GlassScriptPhysician profile
Melanie J Smith
NPI 1871774950
$9,663.56
in general payments reported to CMS, 2019-2025
53 companies · $2,156 in 2025
The $2,156 reported for 2025 was more than what 96% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $752 · 2022: $1,685 · 2023: $2,683 · 2024: $2,388 · 2025: $2,156.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,222 · Education: $5.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,221.56 |
| Education | $5.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,799.12 | 2021-2025 | |
| Abbott Laboratories | $1,103.09 | 2022-2025 | Thoratec Heartmate 3 Lvas Implant Kit, Proclaim, Freestyle Libre 3 |
| Novo Nordisk INC | $796.01 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $793.32 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Glaxosmithkline, LLC. | $598.37 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Amgen INC. | $463.14 | 2021-2025 | Evenity, Prolia, Prolia |
| Astrazeneca Pharmaceuticals LP | $324.41 | 2024-2025 | Airsupra, Farxiga, Breztri |
| Pfizer INC. | $318.86 | 2021-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $285.53 | 2022-2025 | Caplyta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $273.47 | 2021-2025 | Jardiance, Synjardy, Ofev |
| E.R. Squibb & Sons, L.L.C. | $266.63 | 2022-2025 | Eliquis, Camzyos |
| Bayer Healthcare Pharmaceuticals INC. | $240.64 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $205.63 | 2021-2025 | Gardasil 9, Gardasil, Capvaxive |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $201.06 | 2021-2025 | Xifaxan, Trulance |
| Janssen Pharmaceuticals, INC | $144.80 | 2022-2025 | Spravato |
Show all 53 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $143.54 | 2022-2023 | Quviviq |
| Sumitomo Pharma America, INC. | $142.09 | 2023-2025 | Gemtesa |
| Currax Pharmaceuticals LLC | $135.40 | 2021-2024 | Contrave, Onzetra Xsail, Nexlizet |
| Astellas Pharma US INC | $114.07 | 2023-2025 | Veozah, Myrbetriq |
| Phathom Pharmaceuticals, INC. | $111.18 | 2024-2025 | Voquezna |
| Kowa Pharmaceuticals America, INC. | $104.34 | 2022-2023 | Livalo, Seglentis |
| Novartis Pharmaceuticals Corporation | $96.06 | 2022-2023 | |
| Biohaven Pharmaceutical Holding Company LTD. | $87.50 | 2022 | |
| Lundbeck LLC | $84.35 | 2022-2025 | Rexulti |
| Viatris Specialty LLC | $76.45 | 2025 | Yupelri |
| Edwards Lifesciences Corporation | $69.28 | 2022-2023 | |
| Vanda Pharmaceuticals INC. | $62.08 | 2024-2025 | Fanapt |
| Amarin Pharma, INC. | $60.04 | 2021 | |
| Axsome Therapeutics, INC. | $41.90 | 2024-2025 | Auvelity, Sunosi |
| Ardelyx, INC. | $35.82 | 2025 | Ibsrela |
| Antares Pharma, INC. | $35.27 | 2021-2023 | Nocdurna, Tlando, Xyosted |
| Sanofi Pasteur INC. | $30.95 | 2025 | |
| Dexcom, INC. | $29.46 | 2022-2024 | Dexcom G6 Transmitter |
| Biohaven Pharmaceuticals, INC. | $28.09 | 2021 | |
| Exact Sciences Corporation | $27.37 | 2024 | Cologuard Collection Kit |
| Daiichi Sankyo INC. | $25.31 | 2022 | |
| Sanofi-Aventis U.S. LLC | $24.69 | 2021-2023 | |
| Valinor Pharma, LLC | $23.59 | 2024 | Movantik |
| Heartflow, INC. | $21.83 | 2025 | |
| Boston Scientific Corporation | $20.34 | 2023 | Watchman Flx |
| Alexion Pharmaceuticals, INC. | $19.59 | 2024 | Ultomiris |
| Theracosbio, LLC | $18.89 | 2024 | Brenzavvy |
| Medtronic, INC. | $18.71 | 2022 | |
| Harmony Biosciences LLC | $18.47 | 2024 | |
| Collegium Pharmaceutical, INC. | $17.79 | 2023 | Xtampza |
| Otsuka America Pharmaceutical, INC. | $16.98 | 2025 | Rexulti |
| Vivus LLC | $16.70 | 2023 | Qsymia |
| Paratek Pharmaceuticals, INC. | $16.54 | 2024 | Nuzyra |
| Xeris Pharmaceuticals, INC. | $16.41 | 2021 | |
| Tactile Systems Technology INC | $15.74 | 2025 | Nimbl, Flexitouch Plus |
| Halozyme INC | $15.39 | 2023 | |
| Amphastar Pharmaceuticals, INC. | $14.82 | 2024 | |
| Gilead Sciences, INC. | $12.45 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melanie Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.